Trial · NCT04891991
Intravitreal Infliximab for Proliferative Vitreoretinopathy
NCT04891991, Phase 2, Completed, Cairo University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Intravitreal Infliximab for Proliferative Vitreoretinopathy. Trials, record NCT04891991. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04891991
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Intravitreal Infliximab for Proliferative Vitreoretinopathy
- NCT number
- NCT04891991
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 66 participants, actual
- Lead sponsor
- Cairo University
- Conditions
- Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy, Retinal Detachment
- Interventions
- Intravitreal infliximab, Pars plana vitrectomy
- First posted
- 2021-05-19
- Last updated
- 2024-01-19
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Anatomical success | 9 months | Anatomical Success will be defined as stable complete retinal reattachment following pars plana vitrectomy and silicone oil removal. |
| Secondary | Visual acuity | 1, 3, 6, and 9 months | Best corrected visual acuity will be measured at follow up visits using standard Snellen charts. |
| Secondary | Macular structure | 1, 3, 6, and 9 months | Optical coherence tomography will be done at each follow up visit to assess the structure of the macula. |
| Secondary | Macular vascularity | 7 months | Optical coherence tomography angiography will be done at each follow up visit to assess macular vascular density. |
| Secondary | Macular function | 7 months | Macular function will be assessed during follow up visits using multifocal electroretinography |
| Secondary | Single operation success rate | 9 months | The rate of successful retinal reattachment following a single operation will be calculated. |
| Secondary | Recurrence rate | 9 months | Cumulative rate of recurrence of retinal detachment and reoperation following the primary surgery will be calculated during the study period. |
| Secondary | Epiretinal proliferative | 1, 3, 6, and 9 months | The formation of significant epiretinal proliferation will be assessed clinically at each follow up visit. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers14
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04891991
GET https://conductscience.org/api/trials/v1/NCT04891991/registered